Subscribe to RSS
DOI: 10.1055/s-0032-1304572
Glucose Effects on the Peritoneum: What Can We Learn from Rodent Models?
Publication History
received 26 January 2012
first decision 26 January 2012
accepted 30 January 2012
Publication Date:
08 March 2012 (online)

Abstract
During long-term peritoneal dialysis (PD) the peritoneal membrane underlies processes of structural and functional reorganization mediated by high glucose and reactive glucose metabolites that are contained in PD solutions; this process is accompanied by increasing fibrosis. Mechanistically, the peritoneal damage is triggered by the interaction of advanced glycation end-products with their receptor; this is true for rodents as well as for humans. With this knowledge interventional strategies can be tested in rodent models, among them are the lipid soluble vitamin B1 analogue benfotiamine (BF) or detoxifying enzymes such as glyoxalase. Of additional interest is the finding that PD fluids do not only cause local but also systemic damage, in particular renal and cardiovascular. In the case of kidney damage, the intervention with BF was also successful. Taken together, PD can be regarded as a local model for long-term diabetes together with systemic aspects of damage.
-
References
- 1 Kihm LP, Wibisono D, Muller-Krebs S et al. RAGE expression in the human peritoneal membrane. Nephrol Dial Transplant 2008;
- 2 Haslbeck KM, Schleicher E, Bierhaus A et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-291
- 3 Schwenger V, Morath C, Salava A et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207
- 4 Kihm LP, Muller-Krebs S, Klein J et al. Benfotiamine Protects against Peritoneal and Kidney Damage in Peritoneal Dialysis. J Am Soc Nephrol 2011; 22: 914-926
- 5 Haag-Weber M, Kramer R, Haake R et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010; 25: 2288-2296
- 6 Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 1998; 111-112: 137-151
- 7 Muller-Krebs S, Kihm LP, Zeier B et al. Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest 2008; 38: 296-305
- 8 Muller-Krebs S, Kihm LP, Zeier B et al. Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure. Perit Dial Int 2010; 30: 35-40